Enzymatic Basis of Ribosomal Peptide Prenylation in Cyanobacteria

John A. McIntosh,[†] Mohamed S. Donia,[†,§] Satish K. Nair,[‡] and Eric W. Schmidt*,[†]

[†]Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
[‡]Department of Biochemistry, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States

Ⓢ *Supporting Information*

ABSTRACT: The enzymatic basis of ribosomal peptide natural product prenylation has not been reported. Here, we characterize a prenyltransferase, LynF, from the TruF enzyme family. LynF is the first characterized representative of the TruF protein family, which is responsible for both reverse- and forward-O-prenylation of tyrosine, serine, and threonine in cyclic peptides known as cyanobactins. We show that LynF reverse O-prenylates tyrosine in macrocyclic peptides. Based upon these results, we propose that the TruF family prenylates mature cyclic peptides, from which the leader sequence and other enzyme recognition elements have been excised. This differs from the common model of ribosomal peptide biosynthesis, in which a leader sequence is required to direct post-translational modifications. In addition, we find that reverse O-prenylated tyrosine derivatives undergo a facile Claisen rearrangement at 'physiological' temperature in aqueous buffers, leading to forward C-prenylated products. Although the Claisen rearrangement route to natural products has been chemically anticipated for at least 40 years, it has not been demonstrated as a route to prenylated natural products. Here, we show that the Claisen rearrangement drives phenolic C-prenylation in at least one case, suggesting that this route should be reconsidered as a mechanism for the biosynthesis of prenylated phenolic compounds.

INTRODUCTION

Prenylation is a common biochemical modification that has been studied in detail in numerous systems.[1,2] For example, proteins are often farnesylated or geranylgeranylated on cysteine residues, and numerous peptide natural products are known to be prenylated at diverse positions. Prenylation is key to the biological activity of these molecules.[3,4] Several enzyme families have been described that catalyze prenyl transfer, and indeed whole new prenyltransferase (PT) families continue to be discovered.[5−9] For example, the ABBA family has been shown to catalyze aromatic C-prenylation on a variety of substrates,[10] especially ortho to phenolic oxygen. Several ribosomal peptide natural products, such as ComX and the cyanobactins, are prenylated in unique ways that greatly increase the chemical diversity of the resulting compounds.[11−13] PTs for this growing ribosomal peptide natural product group have yet to be enzymatically characterized.[14]

Cyanobactins are a broadly distributed group of ribosomally derived, macrocyclic peptides whose biosynthetic genes are homologous. These compounds are often highly post-translationally modified. Indeed, many cyanobactins are prenylated by dimethylallyl pyrophosphate (DMAPP) on the oxygen atom of serine, threonine, or tyrosine (Figure 1), all of which are biochemically unprecedented reactions in the context of ribosomal peptides. Among cyanobactins, prenylation is known to occur in the "reverse" position (DMAPP 3-carbon) with serine and threonine and in the "forward" position (DMAPP 1-carbon) with tyrosine. However, no obvious candidate PTs exist in cyanobactin gene clusters.[11] By comparing several cyanobactin

pathways discovered by metagenome sequencing, we proposed that the TruF family of proteins might be PTs.[11] Given that the TruF family lacks the typical sequence hallmarks of PTs, we sought to obtain biochemical evidence for this proposal. Consequently, we explored the set of sequenced gene clusters to find a soluble TruF relative for biochemical analysis.[15] Among TruF relatives, one protein, LynF from *Lyngbya aestuarii*,[16,17] could be solubly expressed in *Escherichia coli*. Although the other steps in cyanobactin biosynthesis have been characterized,[18−21] the PT substrate was unknown prior to this study. Consequently, substrate analogues for each possible biochemical step were synthesized, and their products upon reaction with LynF were analyzed (Figure 2). We show here that the LynF/TruF family represents a remarkably broad substrate family of O-prenyltransferases, with LynF prenylating a wide variety of tyrosyl peptides and phenol derivatives. Among biosynthetically relevant substrates, only cyclic peptides are prenylated.

Unexpectedly, reactions catalyzed by LynF led to carbon-prenylated phenolic products. Generally speaking, PTs catalyze electrophilic alkylation of their substrates. In the case of aromatic substrates, reactions are thought to proceed via electrophilic aromatic substitution.[10] However, several alternative mechanisms exist. For one, it has been proposed since at least the early 1970s that C-prenylated phenols might also arise via reverse O-prenylation of phenols followed by a Claisen rearrangement (Figure 1).[22] This chemical proposal was exploited in several elegant 'biomimetic' total

syntheses of complex natural products.[23,24] Despite a resurgence of biochemical studies of aromatic PTs in recent years,[6,8,10,25−30] the Claisen rearrangement proposal has not been revisited. Here, in addition to characterizing a novel PT family, we show that enzymatically synthesized aromatic C-prenylated phenols can indeed arise via the Claisen rearrangement pathway.


Figure 1. Prenylation in natural products. (A) Representative cyanobactin peptide natural products, showing groups derived from DMAPP in blue. (B) Two possible enzymatic mechanisms of phenol *ortho*-C-prenylation. First, DMAPP is dephosphorylated to yield a cation that can react either at oxygen (pathway I) or at carbon (pathway II). In principle, a Claisen rearrangement from pathway I could then yield the C-prenylated product. Only pathway II has been previously linked to enzymatic modification.

RESULTS

Expression of LynF and Synthesis of Substrates. We found that several of the TruF-group PTs were difficult to overexpress. Fortuitously, in our search for candidate PTs, LynF (44% amino acid identity with TruF1), from the *lyn* pathway of the cyanobacterium *L. aestuarii*, was readily expressed in *E. coli* in soluble form. We predicted that LynF should prenylate phenols, but there are no known natural products of the *lyn* pathway.[16,17] Therefore, analogues of possible substrates were synthesized, including linear peptides representing putative pathway intermediates as well as *cyclo*[APMPPYP] (**6**), which is similar to the predicted *lyn* pathway product (Figure 2, Table 1). Additionally, reactions with several wholly unnatural phenol derivatives and linear peptides containing tyrosine were attempted. The purity and the identity of the synthetic substrates were assessed spectroscopically.

LynF is a Tyrosine PT. When incubated with DMAPP and $MgCl_2$, LynF catalyzed the prenylation of peptides and a subset of phenols related to tyrosine (Table 1). Mg^{2+} was added because many PTs require it for function.[10] Indeed, LynF does not function in the absence of either Mg^{2+} or Mn^{2+}. Tyrosine prenylation was demonstrated by Fourier-transform ion cyclotron resonance (FT-ICR) and MS/MS fragmentation, which revealed the presence of the expected ions (Table S2, Supporting Information) and also localized the prenylation to tyrosine (Figure S1, Supporting Information).

LynF prenylated several tyrosine-containing substrates and showed a strong preference for reaction with cyclic over linear peptides (Table 1). In contrast to typical ribosomal peptide biosynthesis,[31] LynF did not act on pathway intermediates (**3**−**5**) that still contained a leader sequence or enzyme "recognition elements" (Figures 2 and S1 and S2, Supporting Information). Of biosynthetically relevant


Figure 2. Defining the biosynthetic route to prenylated cyanobactins. Proposed biosynthetic scheme for Lyn pathway showing modification of precursor peptide by heterocyclization, proteolysis, macrocyclization, and prenylation. The first steps in this route are supported by previous enzymological studies, but the timing of prenylation was not known. Enzyme recognition elements are highlighted. Analogues (**3**−**6**) were used to assess prenylation of each possible biosynthetic intermediate and are shown in analogous colors beneath each proposed biosynthetic intermediate. Pro was substituted as an approximate isostere for thiazole in later analogues. No reaction was observed with any intermediate except the final cyclic peptide, showing that prenylation occurs at a late step, after all enzyme recognition elements have been excised.

Table 1. Substrates Assayed[a]

no.	substrate	yield
3	TruLy1 precursor peptide	NR
4	TruLy1 w/3 heterocycles	NR
5	APMPPYPSYDDAE	NR
6	cyclo[APMPPYP]	48%
7	APMPPYP	12%
8	N-acetyl APMPPYP	10%
9	cyclo[APMPPPAPMPPYP]	47%
10	cyclo[APMPPYPAPMPPYP]	43%
11	cyclo[KKPYILP]	37%
12	cyclo[KPYILP]	94%
13	KPYILP	1%
14	boc-L-Tyr	71%
15	boc-D-Tyr	66%
16	boc-4-cyano-L-Phe	NR
17	boc-O-allyl-L-Tyr	NR
18	boc-4-iodo-L-Phe	NR
19	boc-4-methoxy-L-Phe	NR
20	L-Phe	NR
21	N-acetyl-L-Tyr	3%
22	L-Tyr	NR
23	dopamine	NR
24	phenol	NR
25	L-Trp	NR
26	cyclo[QGGRGDWP]	NR
27	QGGRGDWPAYDGE	NR

[a] All yield quantitations are based on HPLC (for **6**−**8** and **14**−**25**) or MS (**3**−**5** and **9**−**13**) analyses of 24 h reactions and do not represent isolated yields. NR ("no reaction") denotes no detectable prenylation of tyrosine or derivatives. All substrates were run at 100 μM except **3**, **4**, and **9**, **10**, **11**, and **12** (14, 14, 70, 30, 20, and 20 μM, respectively). Both full (100 μM) and reduced concentrations (28, 56 μM) were employed with substrates **6** and **14** in order to compare data for substrates tested at reduced concentration.

Figure 3. LynF is *ortho*-C-prenylating. The aromatic/olefin region of the heteronuclear quantum coherence NMR spectra is shown for (A) boc-tyrosine (**14**) and (B) its purified enzymatic product with LynF, clearly indicating a single, forward C-prenylation event. Similar spectra were also observed for reactions containing **6**. NMR and MS characterization of compounds is presented in Figures S1, S3, and S5, Supporting Information.

substrates, LynF acted only on the mature cyclic peptides, such as **6**. Overall, LynF was capable of prenylating a broad variety of cyclic peptides, including substrates (**9**−**12**) containing 6-, 7-, 13-, and 14-amino acid residues. Surprisingly, LynF also prenylated several tyrosine-containing substrates that are not relevant to the natural biosynthetic pathway. Tyrosine itself was not a substrate, but boc-L-tyrosine and other N-terminally blocked tyrosine derivatives were readily prenylated (**14**, **15** and **21**). Derivatives lacking a free phenolic −OH were not substrates (**16**−**20**). Overall, LynF appears to require a blocked N-terminus but otherwise exhibits relaxed substrate specificity.

LynF Products are *ortho*-C-Prenylated. Based upon the known products of cyanobactin pathways, we expected that LynF would catalyze forward O-prenylation of phenol.[11,32] We performed large-scale enzymatic reactions with long incubation times to generate sufficient quantities of products for NMR analysis. Products of two different LynF substrates, **6** and **14**, were isolated by HPLC and characterized by NMR and high-resolution MS. Surprisingly, by comparison to previously described compounds,[33] we established that both **6** and **14** were forward C-prenylated, ortho to the phenolic hydroxyl group (Figures 3 and S3, Supporting Information).

C-Prenylation is the Result of a Claisen Rearrangement. Initially, we assumed that LynF catalyzed electrophilic aromatic

Scheme 1. NMR Characterized Products

substitution at the ortho position in a manner identical with that reported for ABBA PTs. With an eye toward constructing a Hammett plot of reactivity, we assayed the LynF catalyzed prenylation of a series of 4-substituted Tyr derivatives (**16**−**20**) (Table 1). However, all of these reactions failed. If LynF-catalyzed prenylation were to occur via electrophilic aromatic substitution, then one would expect a broader scope of reactivity, as was found for dimethylallyl tryptophan synthase.[34]

An alternative mechanism for the formation of *ortho*-C-prenylated phenols involves reverse O-prenylation followed by Claisen rearrangement of the resulting O-allyl intermediate.[22] In

Figure 4. LynF catalyzes reverse O-prenylation of tyrosine. The aromatic/olefin region of ^{1}H NMR spectra are shown (A) for boc-tyrosine (**14**), (B) the HPLC-purified intermediate LynF product (**31**), and (C) the final reaction product (**30**). These spectra clearly indicate that the first product of the LynF reaction is reverse-O-prenyl tyrosine, which subsequently rearranges to give the C-prenylated product.

Figure 5. Time course of boc-L-Tyr (**14**) reaction followed by HPLC. The reaction was performed in quadruplicate, with variation indicated by error bars (A) and (B). Initial product of the reaction is almost exclusively O-prenylated as shown at 1, 2, and 4 h time points (B). After 4 h, the level of O-prenylated intermediate reaches steady-state and its levels are constant through 24 h, accompanied by steady increase in the concentration of C-prenylated final product **29**. This allowed kinetic constants for the Claisen rearrangement to be directly determined, since at steady state the concentration of the O-prenyl intermediate can be assumed to be a constant.

that vein, careful examination of LC-FT-ICR analyses of reaction mixtures showed that upon reaction with LynF, all substrates gave rise to two products (Figure S1, Supporting Information). These products were isobaric and prenylated on tyrosine. However, one product was prenylated on carbon and the other on oxygen. Forward carbon prenylation had been established using **28** (Scheme 1), which was purified and characterized by NMR as described above. Of the two products of LynF upon reaction with **6**, purified **28** was found to be identical to the early eluting product (Figure S4, Supporting Information). Moreover, no fragmentation of the C-prenyl moiety on **28** could be observed in MS-MS experiments. Similarly, for all LynF products, we observed that the early eluting compound was prenylated on tyrosine but did not lose isoprene in MS-MS, indicating C-prenylation.

In contrast, all late-eluting products evinced prominent loss of isoprene (C_5H_8) in their MS-MS spectra. Loss of C_5H_8 from prenylated phenols is diagnostic of O-prenylation, as shown in previous studies.[35-37] This reaction was more difficult to characterize by NMR, owing to the apparent instability of the O-prenylated products. Fortuitously, we were able to isolate one of these compounds, resulting from reaction of **15** (Figures 4 and S5, Supporting Information). NMR analysis of the purified material confirmed that the product (**31**) was O-prenylated and conclusively demonstrated that O-prenylation occurred in the reverse orientation. Purified **31** was then added to aqueous buffer at 37 °C (for buffer composition see Materials and Methods Section), and it rapidly and spontaneously rearranged to form the forward C-prenylated product **30** which was identical to the previously NMR-characterized product, **29**.

Reverse O-prenylated phenols are known to undergo the Claisen rearrangement to yield forward *ortho*-C-prenylated products.[22,24,38,39] Thus, we realized that if the sole enzymatic reaction catalyzed by LynF were reverse O-prenyltransfer on Tyr, then this would lead to the mixture of products we had consistently observed with all substrates. Alternatively, we supposed that LynF might carry out reverse O-prenyltransfer in addition to direct electrophilic aromatic substitution in the forward direction on carbon. To distinguish between these two possibilities, a kinetic analysis for reactions containing **14** was performed in which C- and O-prenyl products were followed over 24 h in reactions performed in quadruplicate (Figure 5). The O-prenyl product

Figure 6. Phylogenetic analysis of the TruF/LynF family. (A) Tru F-group proteins cluster according to whether natural products are prenylated (top) or nonprenylated (bottom). Chemical products are shown for each TruF-like protein, where they exist. No TruF-like sequence relatives can be identified outside of cyanobactin gene clusters using either BLAST searching or sequence alignments with other PT family proteins, indicating that this is a novel group of PTs. (B) Actual product structures of prenylagaramide (left) and trunkamide (right) pathways; predicted enzymatic product of *lyn* pathway (middle) prior to Claisen rearrangement.

appeared first, with a delayed onset of **29**. After 4 h of reaction time, a steady state was reached in which the rate of prenylation was equal to the rate of the Claisen rearrangement. Interpretation of the kinetic data, which assumed a unimolecular mechanism and steady-state levels of O-prenyl intermediate, yielded a rate of rearrangement of 8.3 μM/h and a rate constant for the Claisen rearrangement (k where rate of Claisen = k^*[O-prenyl intermediate]) of 0.23 h^{-1}. Taken together with the absence of reactivity observed with analogues lacking a free phenolic $-$OH, these data show that the initial enzymatic reaction is reverse O-prenylation, followed by slower conversion to a forward C-prenylated phenol

Having shown that the O-prenylated compound is the product of initial prenyltransfer, we sought to determine whether the rearrangement to the forward C-prenylated compound was enzyme catalyzed. To do so, purified O-prenylated **31** was added to enzyme, buffer, or boiled enzyme. Under all three conditions, **31** was efficiently converted into C-prenylated **30** without any appreciable enzymatic acceleration (Figure S6, Supporting Information).

This spontaneous Claisen rearrangement might seem surprising given that in the synthetic literature, reverse prenylated phenols require elevated temperatures for rearrangement.[24,38] However, these synthetic reactions take place in organic solvents, while we have employed aqueous solvents. Indeed, the speed with which we

have observed reverse O-prenylated phenols to rearrange is unsurprising in light of the known aqueous acceleration of the Claisen rearrangement.[40−45] Here we show by experiment that the rearrangement goes to completion at 37 °C in aqueous buffers. Consequently, our conditions may provide a particularly mild reaction condition for the Claisen rearrangement for use in future synthetic studies.

To further examine the rapid rearrangement observed with **31**, we purchased O-allyl-boc-L-tyrosine and examined it to see if its rearrangement might be accelerated with enzyme or the buffer conditions employed with **31**. In contrast to the prenylated substrates, this compound did not undergo the Claisen rearrangement under the aforementioned conditions. Based upon these results, it seems that the geminal methyl groups adjacent to the phenolic oxygen are required to promote the Claisen rearrangement at relatively low temperatures. This effect can be rationalized as an example of the gem substituent effect, which is believed to accelerate the Claisen rearrangement.[46] Indeed, it has been shown that the presence of bulky substituents α- to oxygen can accelerate the Claisen rearrangement and similar reactions,[47,48] though to the best of our knowledge this is the first direct comparison of these substrates in the aromatic Claisen rearrangement.

Phylogenetic analysis of LynF and homologues nicely rationalizes the observed pattern of reactivity, where LynF is most closely related to TruF1 and PagF (Figure 6). In light of the above biochemical evidence, TruF1 can be assigned the role of a reverse O-prenyltransferase acting on Ser and Thr, while PagF can be assigned the role of a forward O-prenyltransferase acting on Tyr. Thus, that LynF would carry out reverse O-prenylation of Tyr is unsurprising in light of its phylogenetic profile.

Kinetic Measurements. LynF catalyzed reaction rates were measured in triplicate using two different substrates: *cyclo*-[APMPPYP] (**6**), and an unnatural substrate, boc-L-tyrosine (**14**) (Figure S7, Supporting Information). Using HPLC analysis, the turnover numbers for **6** and **14** were similar (14 and 63 h^{-1}, respectively), as were K_m values (4 and 14 mM, respectively). These rates are slower than those typically reported for prenyltransferases.[27,49] However, the apparent slowness of reactions catalyzed by LynF is not unusual when compared with rates observed with other cyanobactin biosynthetic enzymes. Some of these reactions are quite slow, a fact that has been attributed to their extremely broad substrate tolerance and by extension their relatively low affinities for any given substrate.[18−21]

■ DISCUSSION

To the best of our knowledge, LynF represents the first enzymatically characterized PT leading to the synthesis of ribosomal peptide natural products. Further, serine and threonine O-PTs have not been previously described nor have tyrosine O-PTs acting on ribosomal peptides.[14] Although these post-translational modifications are currently known only in the cyanobactin family of natural products, cyanobactins are present in perhaps ∼30% of all cyanobacteria on Earth and therefore constitute a major fraction of bioactive natural products globally.[50] Another salient feature of this enzyme group is that it clearly acts on polypeptide products, while most other natural product DMAPP transferases act on starting amino acids or on small dipeptides. For example, forward O-prenylated tyrosine has recently been characterized in sirodesmin diketopiperazine biosynthesis.[49,51] However, in this case tyrosine itself is the substrate for prenylation, and the product does not result from ribosomal synthesis.

Scheme 2. Claisen Rearrangement Pathway

Phenols themselves are C- or O-prenylated in many small molecule natural products.[10] In all cases that have been characterized so far, it is thought that C-prenylated phenols arise from direct electrophilic aromatic substitution.[10] Although the Claisen rearrangement was long-predicted from 'biomimetic' chemistry, a biochemical demonstration of its relevance as a route to C-prenylated phenols was lacking. Here, we show that the Claisen rearrangement route can indeed occur to afford C-prenylated products (Scheme 2). This route could easily be missed, since the O-prenylated intermediates are short-lived and not easily detected by commonly used analytical methods. For example, the intermediates have extremely weak absorption at $\lambda = 280$ nm, and their fluorescence spectra are different than for unsubstituted or C-prenylated phenols. The rearrangement is relatively rapid and continues even after enzymes have been denatured or inactivated. Given aqueous acceleration of the Claisen rearrangement and the acceleration provided by the geminal methyl groups of the reverse prenylation, the ease with which the Claisen rearrangement might occur in a cellular context has perhaps been underestimated. Overall, forward prenylation via electrophilic aromatic substitution and reverse O-prenylation followed by the Claisen rearrangement will be indistinguishable under many conditions.

We initially expected that the Claisen rearrangement might be enzymatically accelerated. In synthetic chemistry, several guanidinium-based synthetic catalysts of the Claisen rearrangement have been reported.[38,52] Additionally, in the premier example of a biological Claisen rearrangement, chorismate mutase has been calculated to provide rate enhancements of $>10^6$.[53] However, it is clear from our results using purified reverse-O-prenylated **31** that in this case the reaction is spontaneous. Given the spontaneous nature of this transformation and the similarity to other reported Claisen rearrangements, the simplest hypothesis is that **31** proceeds to **30** via the Claisen rearrangement and not via some other, more complicated mechanism.

We have previously shown that proteins in this group were involved in pathways to very sequence-diverse prenylated natural products in vivo,[16] and here we show that purified LynF accepts many different cyclic substrates. This broad specificity is especially remarkable in that LynF substrates share no common sequence features that would provide robust enzyme recognition elements. In ribosomal peptide natural product synthesis, enzymes commonly recognize conserved motifs in a leader peptide, which is subsequently cleaved and discarded, allowing the enzymes to modify diverse sequences.[31] However, in this case the reaction proceeds after the leader sequence and the recognition elements have already been removed.

The structure and catalytic mechanism of this new family of PTs remains to be determined. Although the proteins bear no homology to any other characterized protein outside of cyanobactin gene clusters, it remains possible that they are structurally related to known PTs. However, no putative ABBA-like required residues are present in the correct places in these proteins (Figure S8, Supporting Information). Since PTs are often deeply divergent and sequence similarity is completely lacking for this protein class, a final comparison will await structural study. It is also unknown why nonprenylating cyanobactin clusters usually contain (and even require) LynF-like proteins.[16,50] In these nonprenylating cases, all enzymatic roles have been assigned, so that LynF homologues serve no obvious enzymatic function.[20,21] However, removal of the LynF homologue from heterologous expression of the nonprenylating pat pathway in *E. coli* abolishes compound production.[16] Possible roles include a chaperone function or perhaps interaction with the leader sequence.

In conclusion, we show that the TruF/LynF group of proteins represents a new family of PTs that catalyze unprecedented enzymatic reactions and that are quite distinct from previously characterized proteins. LynF represents the first ribosomal peptide natural product prenyltransferase to be characterized, opening the door to the study of prenylated ribosomal peptide natural products.

■ MATERIALS AND METHODS

For detailed methods, see Materials and Methods in the Supporting Information.

Substrates. Dimethylallyl pyrophosphate (DMAPP) was synthesized following previously established procedures.[54−56] Excepting **11**, **12**, and **26** whose synthesis and characterization has been reported elsewhere,[15,19] peptide substrates were synthesized at the University of Utah DNA/peptide synthesis core facility. Synthesis of boc-protected 4-iodo-L-phenylalanine and 4-methoxy-L-phenylalanine was performed according to previously established procedures.[57] Boc-L-tyrosine, sodium hydrogen pyrophosphate, dimethylallyl bromide, tetrabutylammonium hydroxide, and dopamine HCl were purchased from Sigma. *N*-acetyl-L-tyrosine and phenol were purchased from Fisher Scientific. All other Tyr and Phe derivatives were purchased from ChemImpex.

Genes and Cloning. A codon-optimized version of *lynF* was synthesized and cloned into pET28 in frame with the N-terminal his-tag sequence using NdeI and EcoRI (Genscript). TruLy1 was cloned via modification of a previously described vector,[15] which was subsequently cloned into pET28b using NdeI and BamHI.

Protein Expression and Purification. LynF was expressed in BL21(DE3) cells, purified initially by Ni-NTA chromatography, which was followed by size-exclusion chromatography to yield homogeneous protein. Purification of TruLy1 was likewise performed by Ni-NTA chromatography, with the main difference being that rather than attempting to isolate soluble protein, TruLy1 was strongly overexpressed with the intent of driving the protein into inclusion bodies, after which time purification under denaturing conditions was performed.

Enzyme Assays. Enzyme reactions typically contained enzyme (3.8 μM) and variable substrate concentration (100 μM for most substrates; higher concentrations, i.e., 1 mM, were occasionally employed with boc-protected amino acid derivatives. Exceptions include substrates **11** and **12**, which were used at 20 μM final concentration as well as substrates **9** and **10**, which were used at 70 and 30 μM, respectively). Several additives (1 M of NaCl, 40 mM of glycylglycine pH of 9.0, 12 mM of MgCl$_2$, 3 mM of tris(2-carboxyethyl) phosphine (TCEP), and 1 mM of DMAPP) were added to all reactions. Reactions were incubated at 37 °C for 24 h in a DNA Engine Peltier thermocycler (Bio-Rad). Enzyme reactions with full-length precursor peptide contained TruLy1 (28 μM), ATP (0.8 mM), with or without heterocyclase enzyme TruD (90 nM), and additives as above. Controls were run to ensure that LynF was active in the presence of TruD and TruLy1 and vice versa. Products were characterized by MS or diode array (λ = 220 and 280 nm) and fluorescence (λ = 271 nm excitation and 303 nm emission) HPLC. Reactions assessing the rate of rearrangement of purified **31** were performed at 37 °C with time points taken at 0 and 8 h and included the standard additives described above. For descriptions of specific assays, see Materials and Methods in the Supporting Information.

Phylogenetic Tree Construction. The amino acid sequences of LynF homologues from the functionally characterized cyanobactin pathways were aligned using CLUSTALX. Maximum likelihood analysis with molecular clock PROMLK (PHYLIP) using the bootstrap test method (1000 replicates) was performed to assess the phylogenetic relationship between the different homologues. The same tree branches were also supported using other phylogenetic experiments such as maximum parsimony (MEGA 4.0) using 1000 bootstrap replicates.

General Methods. ESI-MS and FT-ICR analyses were performed at the University of Utah Mass Spectrometry and Proteomics core facility. MALDI-MS analyses were performed on a Micromass MALDI micro MX instrument (Waters). HPLC separations were performed on a LaChrom Elite system (Hitachi). NMR spectra were collected on either 400 or 500 MHz spectrometers (Varian). CD spectra were collected on a Jasco J-815 spectrometer, and data were plotted in Excel.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information. Additional mass spectrometry, NMR, kinetic, protein purification, sequence, and substrate data, and full methods. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author
ews1@utah.edu

Present Addresses
§Department of Bioengineering and Therapeutic Sciences and California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA 94158

■ ACKNOWLEDGMENT

■ REFERENCES

(1) Brandt, W.; Bräuer, L.; Günnewich, N.; Kufka, J.; Rausch, F.; Schulze, D.; Schulze, E.; Weber, R.; Zakharova, S.; Wessjohann, L. *Phytochemistry* **2009**, *70*, 1758–1775.

(2) Nguyen, U. T.; Goody, R. S.; Alexandrov, K. *ChemBioChem* **2010**, *11*, 1194–1201.

(3) Gibbs, R. A. *Nat. Chem. Biol.* **2005**, *1*, 7–8.

(4) Casey, P. J.; Seabra, M. C. *J. Biol. Chem.* **1996**, *271*, 5289–5292.

(5) Sacchettini, J. C.; Poulter, C. D. *Science* **1997**, *277*, 1788–1789.

(6) Edwards, D. J.; Gerwick, W. H. *J. Am. Chem. Soc.* **2004**, *126*, 11432–11433.

(7) Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. *Cell* **1990**, *62*, 81–88.

(8) Kuzuyama, T.; Noel, J. P.; Richard, S. B. *Nature* **2005**, *435*, 983–987.

(9) Gebler, J. C.; Poulter, C. D. *Arch. Biochem. Biophys.* **1992**, *296*, 308–313.

(10) Saleh, O.; Haagen, Y.; Seeger, K.; Heide, L. *Phytochemistry* **2009**, *70*, 1728–1738.

(11) Donia, M. S.; Ravel, J.; Schmidt, E. W. *Nat. Chem. Biol.* **2008**, *4*, 341–343.

(12) Carroll, A. R.; Coll, J. C.; Bourne, D. J.; MacLeod, J. K.; Zabriskie, T.; Ireland, C. M.; Bowden, B. F. *Aust. J. Chem.* **1996**, *49*, 659–667.

(13) Okada, M.; Sato, I.; Cho, S. J.; Iwata, H.; Nishio, T.; Dubnau, D.; Sakagami, Y. *Nat. Chem. Biol.* **2005**, *1*, 23–24.

(14) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. *Nat. Prod. Rep.* **2009**, *26*, 537–559.

(15) Donia, M. S.; Schmidt, E. W. *Chem. Biol.* **2011**, *18*, 508–519.

(16) Donia, M. S.; Hathaway, B. J.; Sudek, S.; Haygood, M. G.; Rosovitz, M. J.; Ravel, J.; Schmidt, E. W. *Nat. Chem. Biol.* **2006**, *2*, 729–735.

(17) Leikowski, N.; Fewer, D. P.; Sivonen, K. *Appl. Environ. Microbiol.* **2009**, *75*, 853–857.

(18) McIntosh, J. A.; Schmidt, E. W. *ChemBioChem* **2010**, *11*, 1413–1421.

(19) McIntosh, J. A.; Robertson, C. R.; Vinayak, A.; Satish, N. K.; Bulaj, G. W.; Schmidt, E. W. *J. Am. Chem. Soc.* **2010**, *132*, 15499–15501.

(20) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. *J. Am. Chem. Soc.* **2010**, *132*, 4089–4091.

(21) Lee, J.; McIntosh, J. A.; Hathaway, B. J.; Schmidt, E. W. *J. Am. Chem. Soc.* **2009**, *131*, 2122–2214.

(22) Quillinan, A. J.; Scheinmann, F. *J. Chem. Soc. D* **1971**, 966–967.

(23) Tisdale, E. J.; Slobodov, I.; Theodorakis, E. A. *Org. Biomol. Chem.* **2003**, *1*, 4418–4422.

(24) Nicolaou, K. C.; Li, J. *Angew. Chem., Int. Ed.* **2001**, *40*, 4264–4268.

(25) Jost, M.; Zocher, G.; Tarcz, S.; Matuscheck, M.; Xie, X.; Li, S. M.; Stehle, T. *J. Am. Chem. Soc.* **2010**, *132*, 17849–17858.

(26) Haagen, Y.; Unsöld, I.; Westrich, L.; Gust, B.; Richard, S. B.; Noel, J. P.; Heide, L. *FEBS Lett.* **2007**, *581*, 2889–2893.

(27) Ding, Y.; de Wet, J. R.; Cavalcoli, J.; Li, S.; Greshock, T. J.; Miller, K. A.; Finefield, J. M.; Sunderhaus, J. D.; McAfoos, T. J.; Tsukamoto, S.; Williams, R. M.; Sherman, D. H. *J. Am. Chem. Soc.* **2010**, *132*, 12733–12740.

(28) Schultz, A. W.; Lewis, C. A.; Luzung, M. R.; Baran, P. S.; Moore, B. S. *J. Nat. Prod.* **2010**, *73*, 373–377.

(29) Balibar, C. J.; Howard-Jones, A. R.; Walsh, C. T. *Nat. Chem. Biol.* **2007**, *3*, 584–592.

(30) Pojer, F.; Wemakor, E.; Kammerer, B.; Chen, H.; Walsh, C. T.; Li, S. M.; Heide, L. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 2316–2321.

(31) Oman, T. J.; van der Donk, W. A. *Nat. Chem. Biol.* **2010**, *6*, 9–18.

(32) Murakami, M.; Itou, Y.; Ishida, K.; Shin, H. J. *J. Nat. Prod.* **1999**, *62*, 725–755.

(33) Ahmed, F.; Ohtsuki, T.; Aida, W.; Ishibashi, M. *J. Nat. Prod.* **2008**, *71*, 1963–1966.

(34) Gebler, J. C.; Woodside, A. B.; Poulter, C. D. *J. Am. Chem. Soc.* **1992**, *114*, 7354–7360.

(35) Donia, M. S.; Schmidt, E. W. *Chem. Biol.* **2011**, *18*, 508–519.

(36) Sobolev, V. S.; Potter, T. L.; Horn, B. W. *Phytochem. Anal.* **2006**, *17*, 312–322.

(37) Miranda, C. L.; Stevens, J. F.; Ivanov, V.; McCall, M.; Frei, B.; Deinzer, M. L.; Buhler, D. R. *J. Agric. Food Chem.* **2000**, *48*, 3876–3884.

(38) Uyeda, C.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2008**, *130*, 9228–9229.

(39) Hoarau, C.; Pettus, R. R. T. *Synlett* **2003**, 127–137.

(40) Bagnell, L.; Cablewski, T.; Strauss, C. R.; Trainor, R. W. *J. Org. Chem.* **1996**, *61*, 7355–7359.

(41) Narayan, S.; Muldoon, J.; Finn, M. G.; Fokin, V. V.; Kolb, H. C.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2005**, *44*, 3275–3279.

(42) Majumdar, K. C.; Alam, S.; Chattopadhyay, B. *Tetrahedron* **2008**, *64*, 597–643.

(43) Knowles, J. R.; Copley, S. D. *J. Am. Chem. Soc.* **1987**, *109*, 5008–5013.

(44) Grieco, P. A. *Aldrichimica Acta* **1991**, *24*, 59–66.

(45) White, W. N.; Wolfarth, E. U. *J. Org. Chem.* **1970**, *35*, 2196–2199.

(46) Jung, M. E.; Piizzi, G. *Chem. Rev.* **2005**, *105*, 1735–1766.

(47) Harfenist, M.; Thom, E. *J. Org. Chem.* **1972**, *37*, 841–848.

(48) Goering, H. L.; Jacobson, R. R. *J. Am. Chem. Soc.* **1958**, *80*, 3277–3285.

(49) Zou, H. X.; Xie, X.; Zheng, X. D.; Li, S. M. *Appl. Microbiol. Biotechnol.* **2011**, *89*, 1443–1451.

(50) Donia, M. S.; Schmidt, E. W.*Comprehensive Natural Products Chemistry II*; Mander, L., Liu, H.-W., Eds.; Elsevier: Oxford, U.K., 2008; Vol. 2, pp 539558.

(51) Kremer, A.; Li, S. M. *Microbiology* **2010**, *156*, 278–286.

(52) Uyeda, C.; Rötheli, A. R.; Jacobsen, E. N. *Angew. Chem., Int. Ed.* **2010**, *49*, 9753–9756.

(53) Andrews, P. R.; Smith, G. D.; Young, I. G. *Biochemistry* **1973**, *12*, 3492–3498.

(54) Woodside, A. B.; Huang, Z.; Poulter, C. D. *Org. Synth.* **1988**, *66*, 211–215.

(55) Woodside, A. B.; Huang, Z.; Poulter, C. D. *Org. Synth.* **1993**, *8*, 616–620.

(56) Davisson, V. J.; Woodside, A. B.; Neal, T. R.; Stremler, K. E.; Muehlbacher, M.; Poulter, C. D. *J. Org. Chem.* **1986**, *51*, 4768–4779.

(57) Stankova, I. G.; Videnov, G. I.; Golovinsky, E. V.; Jung, G. *J. Peptide Sci.* **1999**, *5*, 392–398.